Destum Partners

Bridging the Gap Between Science and Business

admin

By

BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics

SEOUL, South Korea, Jan. 4, 2022 / PRNewswire – BIORCHESTRA and SK Biopharmaceuticals announced today that they have forged a partnership to research and develop new therapeutic compounds targeting microRNAs [1] (miRNA) for a potential treatment of epilepsy.

Under the collaboration agreement, BIORCHESTRA, a South Korea-based privately-held biotech company that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology.

BIORCHESTRA has a platform using antisense oligonucleotides[2] (ASO) to inhibit and regulate miRNA function, and a proprietary drug delivery system (BDDSTM) that penetrates the blood-brain barrier (BBB) and delivers RNA drugs to the brain.

SK Biopharmaceuticals, a global innovative pharmaceutical company, will validate disease-modifying targets, as well as carry out preclinical studies. [Read more…] about BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics

By

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

MENDHAM, N.J. and ROME, ITALY | November 15, 2021 – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and global contract research organization, announced today they entered into an agreement for Antios to purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) being developed for the treatment of HBV. The CAMs were originated and developed at IRBM in conjunction with Promidis/CNCCS (a subsidiary of IRBM), Istituto Nazionale Genetica Molecolare (INGM) and San Raffaele Hospital (OSR). These CAMs enable the selection of a new pipeline candidate, which will be the second molecule in Antios’ HBV portfolio. The total potential value of the deal to the Italian sellers/parties is up to $50 million, in addition to royalties. [Read more…] about Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)